Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536636 | 0.83 | APP (0.48) | GRM5CYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL30694380 | 0.80 | CYP2A6 (0.55) | GRM5CYP2A6CHRNB2CHRNA4CYP2C9 | |
| SCHEMBL2922495 | 0.80 | CYP2A6 (0.55) | GRM5CYP2A6CHRNB2CHRNA4CYP2C9 | |
| SCHEMBL6365168 | 0.79 | APP (0.48) | GRM5CYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL17536641 | 0.78 | GRM5 (0.39) | GRM5CYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL401836 | 0.77 | GRM5 (0.64) | GRM5CYP2A6CHRNB2CHRNA4CYP2C9 | |
| SCHEMBL31673222 | 0.77 | GRM5 (0.64) | GRM5CYP2A6CHRNB2CHRNA4CYP2C9 | |
| SCHEMBL22548041 | 0.75 | GRM5 (0.41) | GRM5 | |
| SCHEMBL3796332 | 0.74 | CYP2A6 (0.67) | GRM5CYP2A6CHRNB2CHRNA4CYP2C9 | |
| SCHEMBL30825998 | 0.74 | GRM5 (0.49) | GRM5CYP2A6CHRNB2CHRNA4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189063-B1 | BASE-CATALYZED SILYLATION OF TERMINIAL ALKYNE C-H BONDS | CALIFORNIA INST OF TECHN (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10072030-B2 | Base-catalyzed silylation of terminal alkyne C—H bonds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-09-11 | — | — | US | disclosed |
| EP-3189063-A1 | BASE-CATALYZED SILYLATION OF TERMINIAL ALKYNE C-H BONDS | California Institute of Technology (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170088563-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | NATIONAL SCIENCE FOUNDATION | 2017-03-30 | — | — | US | disclosed |
| US-20170088563-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | NATIONAL SCIENCE FOUNDATION | 2017-03-30 | — | — | US | disclosed |
| US-9556206-B2 | Base-catalyzed silylation of terminal alkyne C—H bonds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556206-B2 | Base-catalyzed silylation of terminal alkyne C—H bonds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2016036685-A1 | BASE-CATALYZED SILYLATION OF TERMINIAL ALKYNE C-H BONDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036685-A1 | BASE-CATALYZED SILYLATION OF TERMINIAL ALKYNE C-H BONDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160060278-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-03-03 | — | — | US | disclosed |
| US-20160060278-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-03-03 | — | — | US | disclosed |
| US-20160060278-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060278-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | ALKBH3, CA3, ALKBH2 | GRM5 3797/4885CYP2A6 1907/4885CHRNB2 3220/4885 |
| US-20170088563-A1 | BASE-CATALYZED SILYLATION OF TERMINAL ALKYNE C-H BONDS | ALKBH3, CA3, ALKBH2 | GRM5 4034/4885CYP2A6 1691/4885CHRNB2 3388/4885 |
| US-10072030-B2 | Base-catalyzed silylation of terminal alkyne C—H bonds | ALKBH3, CA3, ALKBH2 | GRM5 4027/4885CYP2A6 1656/4885CHRNB2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.